The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.

What are FDC medicines?

FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.

Expert opinions on FDC medicines

Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.

Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.

The risks of FDC medicines

The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.

The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.

With the patent on semaglutide expiring today in India, NATCO Pharma has become the first drugmaker to launch the generic version of the weight-loss drug in the country.

NATCO Pharma’s generic semaglutide injection prices start at INR 1,290 per month.

“NATCO is the first company to offer generic semaglutide in multi-dose vials with customized syringes… It is the most affordable GLP-1 currently in the Indian market as it is approximately 70 percent cheaper in cost than the pen device and 90 percent cheaper than the price of the innovator’s brand,” the Hyderabad-based company said, in a statement.

The company had received approval from the Central Drugs Standard Control Organization (CDSCO) in February 2026 to manufacture and market the drug, after a clinical comparison study.

Semaglutide works by targeting key areas of the brain involved in appetite regulation and food intake. It reduces hunger, improves satiety, and cuts down food cravings, eventually inducing weight loss.

It also improves insulin resistance and has a beneficial effect on the reduction of cardiometabolic events and risk factors.

NATCO's Semaglutide Drugs

NATCO's semaglutide drugs will be sold under brand names SEMANAT and SEMAFULL in multi-dose vial formats. It will be priced:

• INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants,
• INR 1,750 for the 8 mg/3 ml dose.

• INR 4,000 for 2 mg/1.5ml,
• INR 4,200 for 4 mg/3 ml,
• INR 4,500 per month for 8 mg/3 ml.

In comparison, Novo Nordisk's Ozempic and Wegovy in pen devices cost INR 8,800 and INR 10,850, respectively, per month for the starting doses.

NATCO has also signed a distribution partnership with Eris Lifesciences to co-market its therapy in India.

Other Generic Versions

Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences are also expected to introduce their versions of semaglutide on Saturday.

Others in the pipeline include Alkem Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

With intense competition, analysts believe around 50 branded semaglutide generics will enter the Indian market within months, BBC reported.

Calling it a potential "magic-pill moment" for India, investment bank Jefferies predicted that the semaglutide market in the country could reach $1bn domestically.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

End Of Novo Nordisk’s Patents

In January this year, Canada became the first country to lose patent protection for semaglutide. However, the country's health regulator hasn’t approved any generics so far.

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

In view of losing patent, Novo Nordisk recently cut prices for Wegovy in India. The company also launched its blockbuster brand Ozempic in December.

Once affecting people who smoked tobacco, lung cancer in India is today more common among people who never smoked. The major reason: exposure to poor air, almost year-round.

Although air pollution has emerged as an important risk for lung cancer, the evidence on this issue from India is limited. To explore more on this, the All India Institute of Medical Sciences, Delhi, today announced undertaking a major study.

The study, dubbed ‘AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk’, will examine the connection between the fine particulate matter 2.5 (PM 2.5) and the risk of lung cancer in the country.

PM2.5 particles, with a diameter of 2.5 micrometers or less, are approximately 30 times smaller than a human hair. It is a significant yet often unseen threat to air quality.

“India is home to some of the most polluted cities in the world, and there is an urgent need to scientifically look at the effects of pollution on people’s health. Lung cancer is one of the most common cancers among males in India, and there is a high number of non-smoking lung cancers among females and young adults,” said Dr. Abhishek Shankar, Assistant Professor, Radiation Oncology at AIIMS, who will lead the study, while addressing the media.

“It is deeply concerning that lung cancer, once assumed to be a disease mostly associated with people who smoke tobacco, is now seeing a rapid increase in incidence amongst people who do not smoke,” he added.

The expert urged the "need to implement policy and management strategies to tackle this disease and mitigate further loss of life”.

The AIRCARE Study

It will be the first-of-its-kind scientific study in India to evaluate the effects of exposure to air pollution.

About 1,615 lung cancer cases with 1,615 controls from their family members will be added to the study.

The study will employ both a cohort and case-control design to track the effects of chronic PM 2.5 exposure on lung cancer incidence across various demographics and socio-economic groups.

It will also attempt to isolate an Indian population-specific genetic imprint.

Based on the findings, the researchers aim to develop a risk- based screening model that will include both clinical and molecular components specific to the Indian population and exposure levels.

It will also identify the susceptible population among the cohort who are more at risk of developing lung cancer.

Lung Cancer And Air Pollution Risks In India

Data from the National Cancer Registry shows that lung cancer affects about 72,000 people and claims 66,000 lives every year in India -- making it one of the leading causes of cancer mortality in the country.

From a smoker’s illness, lung cancer has now emerged as a major concern due to poor air quality. Several doctors across Delhi and Maharashtra have n noted a significant increase in pulmonary cancer due to air pollution.

A 2025 study at a government hospital in North India found that 52 percent of lung cancer cases were among non-smokers.

The Indian government today constituted the National Dental Commission (NDC), in a major reform to improve the quality of dental education in the country and align it with global standards, said the Ministry of Health and Family Welfare, on the occasion of World Oral Health Day.

The government also announced three autonomous boards under the NDC and repealed the erstwhile Dental Council of India (DCI). The developments were notified on March 19, making the new framework operational from the same date, the Ministry said in a statement.

The NDC aims to introduce essential and long-overdue regulatory reforms in dental education and enhance access to affordable oral healthcare across the country.

The three autonomous bodies aim to support the functioning of the Commission. These are:

• Undergraduate and Postgraduate Dental Education Board -- to oversee dental education
• Dental Assessment and Rating Board -- to regulate accreditation and institutional assessment
• Ethics and Dental Registration Board -- to govern professional conduct and registration of dentists

The key functions of the National Dental Commission includes:

• Framing regulations to implement the provisions of the Act
• Conducting rating and assessment of dental institutions
• Evaluating human resources and promoting dental research
• Framing guidelines for fee regulation in private dental colleges
• Establishing standards for community dental care, education, research, and professional ethics

World Oral Health Day

Every year on March 20, World Oral Health Day is observed to empower people with the knowledge, tools and confidence to secure good oral health.

The 2026 theme is “A Happy Mouth is a Happy Life” raises awareness about the importance of caring for your mouth at every stage of life - from birth through later years.

"Healthy Mouth, Healthy Nation. This World Oral Health Day, let’s raise awareness and take action, practice proper brushing, reduce sugar intake, and prioritize regular dental check-ups. Your smile deserves daily care," the Ministry of Health shared in a post on social media platform X.

Also read: World Oral Health Day: Your Mouth May Signal Disease Before You Even Know, According To Doctor

"A healthy mouth is essential for a healthy body. This World Oral Health Day, let’s focus on building better habits for ourselves and our families," said Union Health Minister JP Nadda.

He called for building up "simple steps like proper brushing, limiting sugary foods, and regular dental check-ups" to maintain good oral health.

"Good oral care not only keeps our smile bright but also supports overall well-being. Let’s use this occasion to raise awareness and commit to maintaining good oral hygiene every day," he added.